JPS5248678A - Hypotensivedrug - Google Patents

Hypotensivedrug

Info

Publication number
JPS5248678A
JPS5248678A JP51119041A JP11904176A JPS5248678A JP S5248678 A JPS5248678 A JP S5248678A JP 51119041 A JP51119041 A JP 51119041A JP 11904176 A JP11904176 A JP 11904176A JP S5248678 A JPS5248678 A JP S5248678A
Authority
JP
Japan
Prior art keywords
hypotensivedrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP51119041A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5543474B2 (enExample
Inventor
Uin Maachin
Kinkuru Jiyarosurabu
Anburosu Daunigan Danieru
Hadorei Jiyoonzu Piitaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24492453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5248678(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JPS5248678A publication Critical patent/JPS5248678A/ja
Publication of JPS5543474B2 publication Critical patent/JPS5543474B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP51119041A 1975-10-14 1976-10-05 Hypotensivedrug Granted JPS5248678A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/621,980 US4026894A (en) 1975-10-14 1975-10-14 Antihypertensive agents

Publications (2)

Publication Number Publication Date
JPS5248678A true JPS5248678A (en) 1977-04-18
JPS5543474B2 JPS5543474B2 (enExample) 1980-11-06

Family

ID=24492453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51119041A Granted JPS5248678A (en) 1975-10-14 1976-10-05 Hypotensivedrug

Country Status (10)

Country Link
US (2) US4026894A (enExample)
JP (1) JPS5248678A (enExample)
AU (1) AU498925B2 (enExample)
CA (1) CA1057754A (enExample)
CH (1) CH602712A5 (enExample)
DE (1) DE2646186A1 (enExample)
FR (1) FR2327787A1 (enExample)
GB (1) GB1517403A (enExample)
MX (1) MX3620E (enExample)
SE (2) SE422685B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5427588A (en) * 1977-08-04 1979-03-01 Abbott Lab 11*44aminoo6*77dimethoxyy 22quinazorinyl**44*22 tetrahydrofroyl* piperadine hydrochloride dihydrate
JPS55145684A (en) * 1979-04-25 1980-11-13 Pfizer Quinazoline antihypertensive
JPH03286800A (ja) * 1990-04-03 1991-12-17 Gunze Ltd 衣類の折畳み装置

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0022481A1 (en) * 1979-06-21 1981-01-21 Mitsubishi Yuka Pharmaceutical Co., Ltd. 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions
HU180708B (en) * 1979-10-11 1983-04-29 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 1,2,4-oxadiazine derivatives
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
US4734418A (en) * 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
EP0237608B1 (de) * 1986-03-21 1992-01-29 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung
YU70890A (en) * 1989-04-21 1992-05-28 Egyt Gyogyszervegyeszeti Gyar Process for obtaining quinazoline derivatives
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
WO1997011698A1 (en) * 1995-09-29 1997-04-03 Merck & Co., Inc. ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
CA2173408C (en) * 1996-04-03 2001-09-04 K.S. Keshava Murthy Process for the manufacture of intermediates suitable to make doxazosin,terazosin, prazosin, tiodazosin and related antihypertensive medicines
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
KR100648869B1 (ko) 1998-09-30 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
KR20070091049A (ko) 2002-12-13 2007-09-06 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CN102657664A (zh) 2003-09-12 2012-09-12 阿勒根公司 用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
CA2500676A1 (en) * 2005-03-11 2006-09-11 Apotex Pharmachem Inc. Preparation of acid addition salts of amine bases by solid phase-gas phase reactions
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
US20070161791A1 (en) * 2006-01-09 2007-07-12 Narsimha Reddy Penthala Process for the preparation of terazosin hydrocloride dihydrate
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
ES2492645T3 (es) * 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
CN103739596A (zh) * 2013-12-10 2014-04-23 刘磊 用于心脑血管疾病的喹唑啉衍生物
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
JPS4966691A (enExample) * 1972-10-30 1974-06-27

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5427588A (en) * 1977-08-04 1979-03-01 Abbott Lab 11*44aminoo6*77dimethoxyy 22quinazorinyl**44*22 tetrahydrofroyl* piperadine hydrochloride dihydrate
JPS55145684A (en) * 1979-04-25 1980-11-13 Pfizer Quinazoline antihypertensive
JPH03286800A (ja) * 1990-04-03 1991-12-17 Gunze Ltd 衣類の折畳み装置

Also Published As

Publication number Publication date
US4026894A (en) 1977-05-31
SE422685B (sv) 1982-03-22
FR2327787B1 (enExample) 1980-10-10
FR2327787A1 (fr) 1977-05-13
US4112097A (en) 1978-09-05
AU1655776A (en) 1978-02-09
SE431208B (sv) 1984-01-23
GB1517403A (en) 1978-07-12
CH602712A5 (enExample) 1978-07-31
AU498925B2 (en) 1979-03-29
CA1057754A (en) 1979-07-03
SE7611379L (sv) 1977-04-15
JPS5543474B2 (enExample) 1980-11-06
DE2646186A1 (de) 1977-04-28
MX3620E (es) 1981-04-02
SE8008533L (sv) 1980-12-04
DE2646186C2 (enExample) 1987-10-29

Similar Documents

Publication Publication Date Title
GB1517403A (en) Dimethoxyquinazolines
GB1518404A (en) Benzisothiazolines
CS831476A2 (en) Barevna obrazovka
BG27526A4 (en) Herbicid antipoison
CS225976A2 (en) Razove ustroji pohanene tlakovym prostredim
AU1175076A (en) Indolylalkylpiperidines
AU1271076A (en) Push-toy
CS254876A2 (en) Zpusob vyroby isolacni omitnute fasady
EG12510A (en) Dregers
GB1519719A (en) Noroxymorphones
AU1169176A (en) Pyrimidinylureas
AU1390276A (en) Anthraquinone-bis-amidines
AU1804476A (en) Phenylbenzofurans
CS188141B2 (en) Ski-brake
AU1804276A (en) 3-phenylbenzofurans
AU1261376A (en) Diarylbutanolamines
AU1100476A (en) Electropaints
AU1616876A (en) Cloches
CS189776A2 (en) Zpusob regenerace paladiovych katalyzatoru
GB1518055A (en) Omega-trialkoxyalkanoates and -alkanethioates
AU1715276A (en) Phenylsulfenylpiperazines
AU1105976A (en) 5-nitrothiazolylimidazolidine
BG27522A3 (en) Fungicœde compositiow
CH610841A5 (en) Skibob
CS384476A2 (en) Elektronicky casovy spinac